Study Characteristics
The search yielded 2,952 unique citations, 31 of which were included in the study (Fig. 1). Thirty-one studies were classified as non-randomized and four as randomized. A total of 2,756 primary QT ACL-reconstructions with a patient age range of 7-58 years and a weighted mean of 24.2 years were included in this study. Of the 31 included studies, 21 featured an adult population (average age ≥18 years) and 10 featured a pediatric population (average age ≤18 years). Fourteen studies used B-QT autografts and 17 used S-QT; most pediatric studies used S-QT (seven out of 10 studies) while adult studies used B-QT and S-QT evenly (11 studies and 20 studies, respectively).
Quality Assessment - Non-randomized Studies
MINORS scores for the seven adequately reported non-comparative studies ranged from one to 12, and scores for the 20 included comparative studies ranged from 15 to 22. Overall, 29% of included non-comparative studies were deemed to be of “moderate” or greater quality and 100% of included comparative studies were of “moderate” or greater quality. In terms of study design, the median level of evidence within the non-randomized studies was III, with 14 level III studies, eight level IV studies, and five level V studies (20).
Quality Assessment - Randomized Studies
Three out of the four included randomized studies were assigned “high” risk of bias in accordance with the Cochrane RoB 2.0 tool, and one studies was assigned to “some” concern of bias. Notably, the risk of bias arising from the randomization process and data collection of these studies was low. Conversely, many studies had some risk of bias arising from issues of selection, lack of blinding, and interpretation of endpoints. All included randomized studies had a level of evidence of II.
Fig. 1 RoB 2.0 assessment for all included randomized studies
Inter-rater Agreement
Inter-rater agreement was strong at all levels of study screening and quality assessment. Cohen’s kappa (κ) was calculated at each stage of the screening process: κ at title screening was 0.80 (SE: 0.02), κ at abstract screening was 0.89 (SE: 0.01), and κ at full text screening was 0.89 (SE: 0.03).
Table 1 Study characteristics for all included non-randomized studies
Author
|
Year
|
Level of evidence
|
MINORS score
|
# primary QT ACL-R
|
# male
|
Graft type
|
Mean age (y)
|
Afana (22)
|
2021
|
5
|
1
|
1
|
1
|
SQT
|
12
|
Aitchison (23)
|
2021
|
3
|
15
|
33
|
20
|
SQT
|
13.7 ± 1.2
|
Baghdadi (24)
|
2021
|
3
|
16
|
169
|
98
|
SQT
|
NR
|
Brinkman (25)
|
2023
|
3
|
16
|
37
|
17
|
SQT
|
23.4 ± 7.0
|
Daniel (26)
|
2024
|
5
|
9
|
60
|
19
|
SQT
|
16.8
|
Fu (27)
|
2019
|
5
|
9
|
57
|
NR
|
BQT
|
NR
|
Gagliardi (28)
|
2019
|
3
|
16
|
157
|
75
|
BQT
|
15.7 ± 1.8
|
Galan (29)
|
2020
|
4
|
9
|
291
|
268
|
BQT
|
23.2
|
Goto (30)
|
2021
|
4
|
|
73
|
0
|
BQT
|
33.8 ± 11.4
|
Greif (31)
|
2022
|
3
|
18
|
124
|
96
|
SQT
|
NR
|
Haley (32)
|
2023
|
3
|
17
|
721
|
387
|
SQT
|
NR
|
Johnston (33)
|
2021
|
3
|
17
|
35
|
28
|
SQT
|
20.0 ± 8.0
|
Komzak (34)
|
2021
|
3
|
15
|
40
|
21
|
BQT
|
29.8
|
Letter (35)
|
2021
|
3
|
19
|
17
|
14
|
SQT
|
25.8 ± 4.9
|
Mutsuzaki (36)
|
2019
|
5
|
7
|
8
|
2
|
BQT
|
41.6 ± 10.6
|
Panos (37)
|
2021
|
3
|
21
|
23
|
16
|
SQT
|
22.0 ± 6.1
|
Parker (38)
|
2023
|
4
|
10
|
70
|
29
|
SQT
|
28.03
|
Pennock (39)
|
2019
|
4
|
17
|
28
|
19
|
SQT
|
14.8 ± 1.3
|
Perez (40)
|
2019
|
4
|
16
|
28
|
17
|
SQT
|
23.07
|
Pomenta Bastidas (41)
|
2022
|
3
|
20
|
20
|
17
|
BQT
|
30.2 ± 2.38
|
Renfree (42)
|
2023
|
4
|
16
|
32
|
13
|
SQT
|
17.6 ± 2.8
|
Retzky (43)
|
2024
|
4
|
18
|
29
|
17
|
SQT
|
13.57 ± 1.12
|
Runer (44)
|
2020
|
3
|
18
|
217
|
127
|
BQT
|
28.9 ± 11.9
|
Runer (45)
|
2023
|
3
|
22
|
45
|
29
|
BQT
|
28.9 ± 11.6
|
Schmucker (46)
|
2021
|
4
|
19
|
223
|
140
|
SQT
|
26.6 ± 8.6
|
Vaughn (47)
|
2022
|
5
|
18
|
22
|
11
|
BQT
|
15
|
Yamasaki (48)
|
2021
|
3
|
12
|
30
|
21
|
BQT
|
24.5 ± 2.6
|
Table 2 Study characteristics for all included randomized studies
Author
|
Year
|
Level of evidence
|
RoB 2.0 overall score
|
# primary QT ACL-R
|
# male
|
Graft type
|
Mean age (y)
|
Irrgang (49)
|
2021
|
2
|
High
|
57
|
38
|
BQT
|
NR
|
Lind (50)
|
2020
|
2
|
Some concerns
|
50
|
29
|
BQT
|
27.2 ± 6.4
|
Sinding (51)
|
2020
|
2
|
High
|
42
|
25
|
BQT
|
28.7 ± 6.4
|
Tang (52)
|
2023
|
2
|
High
|
17
|
17
|
SQT
|
28.06 ± 6.24
|
Fig. 2 PRISMA flowchart for this review
Average B-QT graft dimensions in the adult population
Of the papers featuring an adult population that directly reported on the graft dimensions used, the average B-QT total graft length was 72.5mm (range: 50-90mm), the average bone block length was 18.5mm (range: 15-20mm), the average graft width was 9.9mm (range: 7-12mm), and the average graft diameter was 6.5mm (range: 5-9mm).
Average S-QT graft dimensions in the adult population
For S-QT grafts in the adult population, the average total graft length was 78.8mm (range: 60-100mm), the average graft width was 10.6mm (range: 9-12mm), and the average graft diameter was 8.4mm (range: 5-10mm).
With regards to the numbers of ACL-R performed, the weighted mean graft length, width, diameter, and bone block length among all included adult studies (B-QT and S-QT) were 71.5mm, 10.4mm, 8.4mm, and 19.1mm, respectively.
Average B-QT graft dimensions in the pediatric population
In studies featuring a pediatric population that directly reported on graft dimensions used, the average B-QT total graft length was 70.0mm (range: 60-80mm) the average bone block length was 16.7mm (range: 15-20mm), the average graft width was 9.7mm (range: 7-12mm), and the average graft diameter was 9mm (range: 8-10mm).
Average S-QT graft dimensions in the pediatric population
For S-QT grafts in the pediatric population, the average total graft length was 64.2mm (range: 50-80mm), the average graft width was 9.75mm (range: 9.0mm to 10.5mm, 5 studies), and there was insufficient data to calculate the average graft depth and graft diameter.
With regards to numbers of ACL-R performed, the weighted mean graft length, width, diameter, and bone block length among all included pediatrics studies (B-QT and S-QT) were 66.3mm, 9.6mm, 9.0mm, and15.2mm, respectively.
Table 3 Graft dimensions by population and technique